GCLL* GENE-CELL inc OTC:BB Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GCLL* GENE-CELL inc OTC:BB

GCLL 0.0001000

+150.0%

Mar 7 3:00 PM EDT

Public Reply Prvt Reply Mark as Last Read File

Next 10PreviousNext

To: Can Do Stocks 2 who wrote ()	6/26/2000 6:21:00 PM
From: Can Do Stocks 2	of 6

post from RB...GENE-CELL INC (OTC BB:GCLL) A co. that Very few have found out about. Plain and simple this is a cutting edge small Bio-tech co. that could be a big winner in the Trillion Dollar Bio-race. And if it does well we know what will happen to the price of the stock +++ +++ +++ +++ +++ and so on... The mission of the Company is to become a global leader in stem cell gene therapy by using the Company's technologies to repair and/or compensate for mutations in defective genes. The strength of the Company lies in its novel procedure for microinjecting DNA and proteins into living cells which enables placement of genetic code material into stem cells. The Company's technology can be applied immediately to fill a current need in the pharmaceutical industry by developing cells that are modified and/or mutated at very specific points within the code of a gene. There are currently no direct competitors of the Company, as the technology developed by the Company is unique. To date, about 4,000 diseases have been traced to gene disorders. Among these are cancer, thalassemia and sickle cell anemia. The Company's current focus is to continue development of its technology for gene therapy intervention in chemotherapy resistance, thalassemia, and AIDS. The Company aims to treat many of these illnesses by incorporating the corrective DNA material into the patients' stem cells, along with certain proteins to get the DNA to incorporate itself properly within the existing cell DNA. As of March 21, 2000, issuer had 17,778,412 shares of its $.001 par value common stock outstanding. Float est. at 4 million +

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Next 10PreviousNext